PRINCETON, N.J., Nov. 17, 2015 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that Al Altomari, President and Chief Executive...

Completion of the SECURE Clinical Trial for Twirla® Planned for Second Half of 2016; Resubmission to the FDA Planned for the First Half of 2017...

Company Plans to Complete Clinical Trial in the Second Half of 2016 and File its Resubmission to the FDA in First Half of 2017...

PRINCETON, N.J. , Sept. 3, 2015 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (NASDAQ:AGRX), a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that Al Altomari , President and Chief...

Company on Track to Complete Study Enrollment for Its Combined Hormonal Contraceptive Patch by the End of Third Quarter 2015...

PRINCETON, N.J. , Aug. 27, 2015 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, announced today that management will present at the following...

Continues to Progress Clinical Trial; Patents for Proprietary Platform to Develop New Women's Contraceptive Products Allowed...

Intellectual Property Portfolio Significantly Broadened for Its Proprietary Transdermal Delivery System...

Presentation Scheduled on Wednesday, July 8th, 2015 at 11:15 AM ET...

PRINCETON, N.J., June 30, 2015 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, announced today that its stock has been selected for addition to...